Corrigendum to "A Targeted Release Capsule of Lanthanum Carbonate: A New Efficient Cheap Treatment for Primary Hyperoxalurias" [Volume 10, Issue 2, February 2025, Pages 503-515].
「更正啟事：『Lanthanum Carbonate 標靶釋放膠囊：原發性高草酸尿症的新型高效低價治療方式』（第10卷，第2期，2025年2月，頁503-515）」
Kidney Int Rep 2025-06-09
這是一則針對 DOI 10.1016/j.ekir.2024.11.020 文章的更正通知，主要是修正或補充原文內容。詳細更正內容請參考官方公告或出版商網站。
PubMedDOI♡
站上相關主題文章列表
Corrigendum to "WCN24-2221 NEPHROCALCINOSIS AND LOWER LIMBS TISSUE NECROSIS DUE TO CALCIUM OXALATE DEPOSITS IN A 24-YEAR-OLD PATIENT WITH STAGE 5 CHRONIC KIDNEY DISEASE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Pages S656-S657].
更正：「WCN24-2221 24歲患有第5期慢性腎臟病患者因鈣草酸鹽沉積導致腎鈣化和下肢組織壞死」一文 [<i>Kidney International Reports</i> 2024年4月第9卷第4期補充刊，第S656-S657頁]。
Kidney Int Rep 2024-06-20
Corrigendum to "WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Pages S368-S369].
對於「WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S368-S369]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是其他相關的問題，請提供更多細節！
PubMedDOI
A Targeted Release Capsule of Lanthanum Carbonate: a New Efficient Cheap Treatment for Primary Hyperoxalurias.
針對性釋放的Lanthanum Carbonate 膠囊：一種新的高效且便宜的原發性高草酸尿症治療方法。
Kidney Int Rep 2025-02-24
Corrigendum to "Avoid Preanalytical Errors When Using Urine Biomarkers of Exposure" [<i>Kidney International Reports</i> Volume 10, Issue 1, January 2025, Page 281].
對於「避免在使用尿液暴露生物標記時產生前分析錯誤」的更正 [<i>Kidney International Reports</i> 第10卷，第1期，2025年1月，第281頁]。
Kidney Int Rep 2025-04-14
Corrigendum to "WCN25-3808 NAFLD IN ESRD - PREVALENCE OF NAFLD in ESRD PATIENTS AND EVALUATION OF THERAPEUTIC EFFICACY OF TOCOTRIENOL IN TREATMENT OF NAFLD" [<i>Kidney International Reports</i> Volume 10, Issue 2, Supplement, February 2025, Pages S339-S340].
更正啟事：「WCN25-3808 末期腎臟病（ESRD）中的非酒精性脂肪肝病（NAFLD）—ESRD 患者中 NAFLD 的盛行率及 tocotrienol 治療 NAFLD 療效之評估」[《Kidney International Reports》2025年2月，第10卷，第2期，增刊，S339-S340頁]
Kidney Int Rep 2025-04-30
Erratum to "Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome" [<i>Kidney International Reports</i> Volume 9, Issue 10, October 2024, Pages 3053-3056].
「『Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome』一文的勘誤啟事」
Kidney Int Rep 2025-04-30
Corrigendum to "Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy" [Volume 10, Issue 1, January 2025, Pages 217-226].
更正啟事：「ALIGN 隨機對照研究 Atrasentan 用於 IgA Nephropathy 患者之研究設計與基線特徵」[第10卷，第1期，2025年1月，頁217-226]
Kidney Int Rep 2025-04-30
重點摘要：
這則通知是用來更正 DOI 為 10.1016/j.ekir.2024.10.004 的文章。內容很可能是針對該篇發表的錯誤進行修正，或是提供相關的最新更新。
PubMedDOI
Corrigendum to "The Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota" [Volume 10, Issue 2, February 2025, Pages 522-534].
「更正啟事：'Bromodomain and Extraterminal Protein Inhibitor Apabetalone 透過調節膽固醇累積及腸道菌相，改善糖尿病腎損傷'【第10卷，第2期，2025年2月，522-534頁】」
Kidney Int Rep 2025-06-09
Corrigendum to "SAT-040 RENAL SAFETY OF DIRECT ACTING ANTIVIRAL DRUGS IN POST LIVER TRANSPLANT PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION" [Volume 5, Issue 3, Supplement, March 2020, Pages S18-S19].
「SAT-040 直接作用型抗病毒藥物於肝臟移植後慢性 C 型肝炎患者之腎臟安全性」更正啟事 [第5卷，第3期，增刊，2020年3月，S18-S19頁]
Kidney Int Rep 2025-06-09